Biogen Data At 2016 AAN Annual Meeting Highlight Its Expansive Portfolio Of MS Therapies That Meets Diverse Needs Of Patients

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) will present new data demonstrating the breadth and diversity of its marketed and pipeline multiple sclerosis (MS) therapies at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada, the company announced today. These data support Biogen’s established portfolio, which includes the most-prescribed oral MS treatment in the world, TECFIDERA® (dimethyl fumarate), and demonstrate the ability of its differentiated products to meet the distinct needs of people living with MS.